A5045403568- Prostate Cancer Treatment and Research
- Bladder and Urothelial Cancer Treatments
- Prostate Cancer Diagnosis and Treatment
- Urinary and Genital Oncology Studies
- Renal cell carcinoma treatment
- Urological Disorders and Treatments
- Urologic and reproductive health conditions
- Genital Health and Disease
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Cancer, Lipids, and Metabolism
- Renal and related cancers
- Epigenetics and DNA Methylation
- Immunotherapy and Immune Responses
- Genetic Associations and Epidemiology
- Radiomics and Machine Learning in Medical Imaging
- Ureteral procedures and complications
- Global Cancer Incidence and Screening
- Ferroptosis and cancer prognosis
- Cancer Research and Treatments
- Tea Polyphenols and Effects
- Bioinformatics and Genomic Networks
- Health Systems, Economic Evaluations, Quality of Life
- MRI in cancer diagnosis
- Testicular diseases and treatments
Moffitt Cancer Center
2016-2025
University of Tampa
2013-2020
University of South Florida
2006-2019
University of Colorado Denver
2016
University of Colorado Cancer Center
2016
Program Support Center
2016
Livestrong Foundation
2015
The Barbara Ann Karmanos Cancer Institute
2015
The University of Texas MD Anderson Cancer Center
2015
Memorial Sloan Kettering Cancer Center
2015
The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis, risk stratification and workup, treatment options localized disease, management of recurrent advanced disease clinicians who treat patients with prostate cancer. portions the guidelines included herein focus on roles germline somatic genetic testing, nomograms tumor multigene molecular androgen deprivation therapy, secondary hormonal chemotherapy, immunotherapy in
In the late 1980s and early 1990s, number of newly diagnosed prostate cancers in United States increased dramatically, surpassing lung cancer as most common men. 1 Experts generally believe that these changes resulted from prostate-specific antigen (PSA) screening detected many earlystage cancers.For example, percentage patients with low-risk disease has (45.3% 1999-2001 vs. 29.8% 1989-1992; P < .0001). 2 The incidence 2.0% annually 1995 to 2001 since declined.In 2009, an estimated 192,280...
The NCCN Guidelines for Prostate Cancer address staging and risk assessment after an initial diagnosis of prostate cancer management options localized, regional, metastatic disease. Recommendations disease monitoring, treatment recurrent disease, systemic therapy castration-recurrent also are included. This article summarizes the Panel's most significant discussions 2016 update guidelines, which include refinement stratification methods new men with high-risk very-high-risk progressive...
The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis include management options localized, regional, metastatic disease. Recommendations disease monitoring treatment of recurrent are also included. Panel meets annually to reevaluate update their recommendations based on new clinical data input from within Member Institutions external entities. This article summarizes the panel’s discussions 2021 guidelines with regard systemic therapy...
Prostate cancer has surpassed lung as the most common in men United States. The NCCN Guidelines for Cancer provide multidisciplinary recommendations on clinical management of patients with prostate based evidence and expert consensus. Panel guidance treatment decisions localized disease is represented this version. Significant updates early include distinction between active surveillance observation, a new section principles imaging, revisions to radiation recommendations. full version these...
The NCCN Guidelines for Prostate Cancer provide a framework on which to base decisions regarding the workup of patients with prostate cancer, risk stratification and management localized disease, post-treatment monitoring, treatment recurrence advanced disease. sections included in this article focus metastatic castration-sensitive nonmetastatic castration-resistant cancer (CRPC), CRPC (mCRPC). Androgen deprivation therapy (ADT) intensification is strongly recommended cancer. For CRPC, ADT...
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer provide multidisciplinary recommendations the clinical management of patients with prostate cancer. These Insights highlight notable recent updates. Abiraterone acetate is a first-in-class hormonal agent that represents new standard care metastatic castration-recurrent cancer who have previously received docetaxel (category 1 recommendation). also category 2B prechemotherapy setting asymptomatic or...
The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis include management options localized, regional, recurrent, metastatic disease. Panel meets annually to reevaluate update their recommendations based on new clinical data input from within Member Institutions external entities. These Insights summarizes much of the panel's discussions 4.2022 1.2023 updates guidelines regarding systemic therapy cancer.
The NCCN Guidelines for Prostate Cancer include recommendations staging and risk assessment after a prostate cancer diagnosis the care of patients with localized, regional, recurrent, metastatic disease. These Insights summarize panel's discussions 2024 update to guidelines regard initial stratification, management very-low-risk disease, treatment nonmetastatic recurrence.
The NCCN Guidelines for Prostate Cancer provide multidisciplinary recommendations on the clinical management of patients with prostate cancer. This report highlights notable recent updates. Radium-223 dichloride is a first-in-class radiopharmaceutical that recently received approval treatment symptomatic bone metastases and no known visceral disease. It category 1 recommendation as both first-line second-line option. Panel also revised choice intermittent or continuous androgen deprivation...
Neoadjuvant chemotherapy (NAC) followed by radical cystectomy improves survival compared with alone for patients bladder cancer. Although gemcitabine cisplatin has become a standard NAC regimen, dose-dense combination of methotrexate, vinblastine, doxorubicin, and (ddMVAC) is being adopted at some institutions.To assess the association neoadjuvant ddMVAC vs regimens downstaging overall among treated cancer.Cross-sectional analysis data extracted from medical records consecutive sample, after...
Abstract Preclinical, epidemiologic, and prior clinical trial data suggest that green tea catechins (GTC) may reduce prostate cancer risk. We conducted a placebo-controlled, randomized of Polyphenon E (PolyE), proprietary mixture GTCs, containing 400 mg (−)-epigallocatechin-3-gallate (EGCG) per day, in 97 men with high-grade prostatic intraepithelial neoplasia (HGPIN) and/or atypical small acinar proliferation (ASAP). The primary study endpoint was comparison the cumulative one-year rates on...
The authors conclude that the overall rate of documentation is low and results show disparities among specific groups. While greater numbers discussions may be occurring, there need to create interventions improve documentation.
Abstract AIMS To evaluate the effectiveness of supplementing a group early stage prostate cancer patients, with 60 mg soy isoflavones in producing change hormonal and proliferative risk parameters that are implicated promotion. METHODS Seventy six eligible patients Gleason score 6 or below, between ages 50 80 were admitted supplemented placebo for 12 week period changes PSA steroid hormones analyzed at baseline post intervention. RESULTS Fifty‐nine completed 12‐week Serum free testosterone...
Abstract BACKGROUND Patients diagnosed with localized prostate carcinoma need to interpret complicated medical information make an informed treatment selection from among treatments that have comparable efficacy but differing side effects. The authors reported initial results for decision‐making strategies men receiving definitive carcinoma. METHODS One hundred nineteen treated radical prostatectomy (44%) or brachytherapy (56%) consented participate. Guided by a cognitive‐affective theoretic...
BACKGROUND Several investigators have tried to apply salvage focal prostate cryoablation small numbers of patients with biopsy-proven unilateral recurrent cancer (PCa) after radiotherapy the aim decreasing complications cryoablation. We report contemporary outcomes for locally PCa within Cryo On-Line Data (COLD) Registry. METHODS queried COLD Registry identify diagnosed as and treated Patients hormone ablation cryotherapy were excluded. The biochemical disease-free survival morbidities...
To assess the potential complications associated with inguinal lymph node dissection (ILND) across international tertiary care referral centres, and to determine prognostic factors that best predict development of these complications.A retrospective chart review was conducted four cancer centres. The study population 327 patients underwent diagnostic/therapeutic ILND. endpoint overall incidence their respective severity (major/minor). Clavien-Dindo classification system used standardize...
The refinement in the localization of prostate cancer tumor foci through transperineal template-mapping biopsies and MRI has led to an increased interest lesion-directed focal prostatic cryoablation. Data are lacking, however, that compare outcomes whole-gland (WG) ablation therapy (FT). aim our study was assess both oncologic functional between WG FT cryoablation after having matched patients for preoperative characteristics.We with a 1:1 ratio 317 men who underwent treatment Cryo Online...
A reason that the immune system may fail to reject tumors is T cells encounter tumor antigen derived peptides on surface of in a tolerizing rather than activating context since do not express cell co-stimulatory molecules such as B7-1 (CD80). In preclinical models over expression has been shown activate which kill cells. We conducted phase I clinical trial testing this approach patients with metastatic renal carcinoma.Resected from 15 were disaggregated and adapted tissue culture, transduced...